S. Tulyte

发表

Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective–prospective cohort multicentre study

V. Urbonas, A. Česas, R. Jančiauskienė, 2023, Journal of Cancer Research and Clinical Oncology.

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)

P. Ascierto, M. Del Vecchio, I. Krajsová, 2021, Cancers.

Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)

A. Poprach, G. Hospers, G. Long, 2019, Melanoma research.

Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine.

T. Žvirblis, D. Characiejus, R. Matuzevičienė, 2023, International immunopharmacology.